BÁBeatriz Álvarez

Beatriz Álvarez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatriz Álvarez has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Profiling to Guide Fertility Sparing Therapy in Early-Stage Endometrial Cancer: A EORTC Gynaecological Cancer Group Study

    by Ramon Yarza, Reyes Oliver-Pérez, Eva Oldenburger, Lawrence Kasherman, Shira Peleg Hasson, José Manuel Estrada-Lorenzo, Beatriz Álvarez-Rodríguez, Alberto Martinez de Lara, Fernanda Herrera, Judith Kroep, et al.

    Objective: Fertility-preserving therapies are a potential option for selected patients with early-stage endometrial cancer and atypical endometrial hyperplasia/endometrial intraepithelial neoplasia. This systematic review aims to evaluate the impact of fertility-preserving strategies according to molecular subtype. Methods: A comprehensive search was conducted in PubMed, Cochrane Library, EMBASE, and Web of Science for English-language studies published until June 2024, investigating fertility-sparing treatments using endocrine therapy in early-stage endometrial cancer, considering molecular classification. The PRISMA checklist was followed, and the protocol was registered in PROSPERO (CRD42025649342). Data on body mass index (BMI), age, and molecular classification (POLE-mutant, non-specific molecular profile [NSMP], p53-abnormal, and mismatch repair deficient [dMMR]) were extracted. The study assessed objective response rates (ORR), pregnancy outcomes, and survival outcomes. Statistical analyses were performed using R software. Results: The search identified 941 articles, and 10 studies with 457 patients were selected for final analysis. Pregnancy outcomes were reported in three studies, whilst all reported ORR data. Baseline median age (dMMR 35 years, POLE-mutant 38.2 years, p53-abnormal 33.9 years, and NSMP 31.6 years) and BMI (dMMR 24.3, POLE-mutant 27.9, p53-abnormal 26.2, and NSMP 29.8) differed by molecular subtype. Aggregated full-term delivery rates from the three studies reporting pregnancy outcomes were 36.4% (4/11) for POLE-mutant, 22.1% (27/122) for NSMP, 14.3% (1/7) for p53-abnormal, and 4.0% (1/25) for dMMR tumours, but statistical comparison was not feasible due to small sample size. Overall response rate was highest in NSMP (87.4%) and POLE-mutant tumours (84.6%), while dMMR (59.3%) and p53-abnormal (58.8%) had significantly lower ORR (compared to NSMP, p < 0.001 and p = 0.03, respectively). Conclusions: These findings support the potential role of molecular classification in refining patient selection for fertility-sparing treatment in early-stage endometrial cancer. Pregnancy-related outcomes should be interpreted with caution given the limited available evidence.

  • Total neoadjuvant therapy with dose-escalated radiotherapy for organ preservation in locally advanced rectal cancer: real-world outcomes

    by O. Hernando-Requejo, M. López González, C. Saiz Guisasola, E. Sánchez Saugar, A. Montero Luis, R. Ciervide Jurio, X. Chen Zao, B. Álvarez Rodríguez, J. Valero Albarran, M. García-Aranda Pez, et al.

    To evaluate the role of total neoadjuvant therapy (TNT) in locally advanced rectal cancer, focusing on its impact on compliance, tumor downstaging, and organ preservation when combined with watch-and-wait (W&W) protocols and to assess whether radiotherapy dose escalation may increase clinical complete response (cCR) rates. We retrospectively analyzed 135 patients with locally advanced rectal cancer treated with TNT and radiotherapy dose escalation (57.5 Gy to the tumor and nodes in 23 fractions) between 2015 and 2024. Patients achieving cCR were considered for the W&W strategy. Outcomes included tumor response, local control, disease-free survival (DFS), and toxicity. Prognostic factors were explored through univariate and multivariate analyses. A total of 48.9% achieved cCR and were managed nonoperatively, while 51.1% underwent surgery. Local control at 3 years was 83.5%, with local regrowth significantly higher in the W&W group (33.1%) than the rate of local recurrences in the surgical cohort (6.5%, p = 0.001). Poorer local control was associated with low rectal tumors, local regrowth, and the development of metachronous metastases. Disease-free survival at 3 years was 69.2%, with better outcomes in patients who underwent surgery or were included in the W&W strategy based on multidisciplinary consensus. No acute or chronic radiotherapy-related toxicity greater than grade 3 was observed. In multivariate analysis, local regrowth and nonconsensual W&W inclusion remained independent predictors of impaired DFS and metastasis-free survival. Total neoadjuvant therapy with radiotherapy dose escalation is effective and well tolerated. Tumor location, local regrowth, and the role of multidisciplinary decision-making are critical prognostic factors. Careful patient selection and structured follow-up are essential to optimize outcomes in the W&W strategy. Although functional and quality of life outcomes were not assessed, future prospective studies should incorporate these measures to further strengthen organ-preservation approaches.

  • Implementing a low-dose radiation therapy program for musculoskeletal pain disorders: tips, tricks, and essentials for clinical researchers

    by Beatriz Álvarez, Angel Montero, Jeannette Valero, Mercedes López, Raquel Ciérvide, Ovidio Hernando, Emilio Sánchez, Miguel Angel de la Casa, Xin Chen-Zhao, Mariola García-Aranda, et al.

    Introduction Painful musculoskeletal disorders (PMDs) represent an increasing public health concern, particularly among aging populations. When conservative therapies prove insufficient, low-dose radiotherapy (LDRT) has emerged as a non-invasive and effective treatment alternative. Despite growing clinical evidence supporting its efficacy, LDRT remains underutilized due to persistent skepticism and the absence of standardized clinical guidelines. Materials and methods This review synthesizes current evidence on the use of LDRT for PMDs, focusing on its biological mechanisms, optimal dosing regimens, clinical efficacy, and safety profile. Attention is given to dose fractionation strategies, timing of re-irradiation, and technological advancements that enhance treatment precision. Results LDRT provides pain relief in 60–90% of treated cases, with the most favorable results achieved using fraction doses between 0.3 and 0.7 Gy. Its anti-inflammatory effects are mediated through immune modulation, reduced proinflammatory cytokine expression, and promotion of tissue repair. Re-irradiation performed 10–12 weeks after the initial cycle may be beneficial in patients experiencing symptom persistence or recurrence. Long-term follow-up data confirm sustained efficacy and indicate a minimal risk of radiation-induced malignancies in older adults. Conclusion LDRT is a safe and effective treatment option for PMDs, especially in patients unresponsive to conventional therapies. To facilitate its broader adoption, this review underscores key clinical evidence and proposes practical considerations for integrating LDRT into multidisciplinary pain management protocols.


  • Open Access

    Achieving complete metabolic response in stage IV lung adenocarcinoma with chemotherapy, nivolumab, ipilimumab, and salvage SBRT: A case report

    by Salvador Gamez Casado, Javier David Benitez Fuentes, Beatriz Álvarez Rodríguez, Gema García Ledo

    Oncogene‐negative, PDL1‐negative metastatic non‐small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55‐year‐old male patient with oncogene‐negative, PDL1‐negative stage IV lung adenocarcinoma, showcasing an exceptional complete metabolic response to a multimodality treatment combining double immune checkpoint inhibition (ICI) and chemotherapy, followed by salvage stereotactic body radiotherapy (SBRT). The patient underwent a treatment regimen incorporating two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab followed by nivolumab, and ipilimumab maintenance. After a partial response, SBRT was applied to persistent lesions, achieving a complete metabolic response. This case highlights the potential of combining dual ICI with chemotherapy and SBRT in treating oncogene‐negative, PDL1‐negative NSCLC underscoring the importance of multimodality treatment strategies.


  • PO-1114 Single isocenter Multitarget Radiosurgery and multiple brain metastases: Preliminary Experience

    by R. Ciervide, M. López, J. Martí, O. Hernando, B. Álvarez, Á. Montero, E. Sánchez, M. García-Aranda, J. Valero, X. Chen, et al.

  • PD-0655 Stereotactic ablative radiosurgery (SABR) for spinal metastases: 12-years of experience

    by R. Ciervide, O. Hernando, M. Lopez, A. Montero, E. Sanchez, B. Alvarez, M. Garcia-Aranda, J. Valero, X. Chen, K. Rossi, et al.

  • Moderate hypofractionated radiation therapy and pathologic response for soft tissue sarcomas (STS) of limbs and trunk: experience from a tertiary cancer center

    by Angel Montero, Xin Chen-Zhao, Raquel Ciérvide, Beatriz Álvarez, Alejandro Prado, Mercedes López, Emilio Sánchez, Ovidio Hernando, Miguel Angel de la Casa, Mariola García-Aranda, et al.

    Background Preoperative radiation therapy following by limb-sparing or conservative surgery is a standard approach for limb and trunk STS. Data supporting hypofractionated radiotherapy schedules are scarce albeit biological sensitivity of STS to radiation would justify it. We sought to evaluate the impact of moderate hypofractionation on pathologic response and its influence on oncologic outcomes. Material and methods From October 2018 to January 2023, 18 patients with limb or trunk STS underwent preoperative radiotherapy at a median dose of 52.5 Gy (range 49.5–60 Gy) in 15 fractions of 3.5 Gy (3.3-4 Gy) with or without neoadjuvant chemotherapy. A favorable pathologic response (fPR) was considered as ≥ 90% tumor necrosis on specimen examination. Results All patients completed planned preoperative radiotherapy. Eleven patients (61.1%) achieved a fPR, and 7 patients (36.8%) a complete pathologic response with total disappearance of tumor cells. Nine patients (47%) developed grade 1–2 acute skin toxicity, and 7 patients (38.8%) had wound complications on follow-up. With a median follow-up of 14 months (range 1–40), no cases of local relapse were observed, and actuarial 3-year overall survival (OS) and distant metastases-free survival (DMFS) are 87% and 76.4%, respectively. In the univariate analysis, the presence of a favorable pathologic response (fPR) was associated with improved 3-year OS (100% vs. 56.03%, p = 0.058) and 3-year DMFS (86.91% vs. 31.46%, p = 0.002). Moreover, both complete or partial RECIST response and radiological stabilization of the tumor lesion showed a significant association with higher rates of 3-year distant metastasis-free survival (DMFS) (83% vs. 83% vs. 56%, p < 0.001) and 3-year overall survival (OS) (100% vs. 80% vs. 0, p = 0.002). Conclusions Preoperative moderate hypofractionated radiation treatment for STS is feasible and well tolerated and associates encouraging rates of pathologic response that could have a favorable impact on final outcomes.


  • Open Access

    Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

    by Raquel Ciérvide, Ángel Montero, Eduardo García-Rico, Mariola García-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benassi, Maria José Barrera, Estela Vega, Beatriz Rojas, et al.

    Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio–chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation was delivered concomitantly during the first 3 weeks of chemotherapy, and it was based on a 15 fractions scheme, 40.5 Gy/2.7 Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy (CT) was based on Pertuzumab–Trastuzumab–Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. A total of 58 patients were enrolled; 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved >90% loss of invasive carcinoma cells in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype, respectively, achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies were applied simultaneously: fractionation of RT (radiotherapy) in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.


  • Open Access

    Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination

    by Raquel Ciérvide, Angel Montero Luis, Eduardo García-Rico, Mariola Garcia-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benasi, Maria Jose Barrera, Estela Vega, Beatriz Rojas, et al.

    Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation is delivered concomitantly during the first 3 weeks of chemotherapy, and it is based on a 15 fractions scheme (40.5Gy/2.7Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy is based on Pertuzumab-Trastuzumab-Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. 58 patients were enrolled, 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved >90% loss of invasive carcinoma cell in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype respectively achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies are applied simultaneously: fractionation of RT in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.

  • Low-dose radiation therapy for hand osteoarthritis: shaking hands again?

    by B. Álvarez, A. Montero, R. Alonso, J. Valero, M. López, R. Ciérvide, E. Sánchez, O. Hernando, M. García-Aranda, J. Martí, et al.

    Background Hand osteoarthritis (HOA) is one of the most common causes of pain and functional disability in western countries and there is still no definitive cure. Low-dose radiation therapy (LDRT) has anti-inflammatory properties that have shown to be effective in the symptomatic relief of various degenerative musculoskeletal disorders. We designed a clinical protocol using LDRT for symptomatic HOA and present results and tolerance in the first 100 patients included. Materials and methods Between April 2015 and March 2021, 100 patients with a median age of 60 were treated. Fifty-seven patients suffering from proximal/distal interphalangeal joint pain, 40 patients with thumb arthritis, 2 patients with radiocarpal joint affection and 1 patient with metacarpophalangeal joint pain were enrolled. LDRT comprised of 6 fractions of 0.5–1 Gy on every other day up to a total dose of 3–6 Gy. Clinical response was evaluated according to the visual analog scale (VAS) for pain level and the von Pannewitz score (VPS) for joint functionality. Any patients not achieving subjective adequate pain relief after 8 weeks of treatment were offered a second identical LDRT course. Results With a median follow-up of 10.5 months (range 7.55–12.45), 94% reported an improvement in the pain, with a significant reduction in the VAS level after 3, 6 and 12 months (p < 0.001). Sixty-three patients needed a second course of treatment at a median time interval of 12 weeks (range 9–14). The mean VAS score before treatment was 8 (range 3–10). After treatment, it was 5 (range 1–10). After 3, 6 and 12 months, the mean VAS scores were 4 (range 0–9), 3 (range 0–9) and 3.5 (range 0–9), respectively. Seventy patients reported functionality improvements after LDRT according to the von Pannewitz score. No acute or late complications were observed. Conclusion LDRT appears to be safe and useful for HOA and is associated with good rates of pain relief and functionality improvements. However, further studies are necessary to confirm these promising results.